At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 307 enrolled
Drug / intervention
LCZ696 +2 moredrug
Likely dose
LCZ696 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 36-week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction
In Brief
A Phase 2 clinical trial evaluating LCZ696, Valsartan, and 1 other intervention for Chronic Heart Failure. Completed, enrolled 307 participants across 81 sites in 14 countries.
Detailed Summary
The study will assess the effects of 36 weeks of treatment with LCZ696 compared to valsartan on N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) in patients with chronic heart failure and preserved left-ventricular ejection fraction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Heart Failure
CountriesArgentina, Brazil, Canada, Germany, India, Italy, Netherlands, Poland, Romania, Russia, Singapore, Spain, United States, Venezuela
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2009
Enrollment StartNov 2009
Primary CompletionDec 2011
TodayJul 2026
First PostedApr 24, 2009
Enrollment StartNov 1, 2009
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 17.2 years ago
Interventions
LCZ696drug
50 mg, 100 mg and 200 mg tablets
Valsartandrug
40 mg, 80 mg and 160 mg tablets
Placebodrug
matching placebo to LCZ696 and Valsartan